Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.

NCT03836066 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT03836066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03836066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Study of Atezolizumab in Combination With Bevacizumab as First Line Treatment for Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous Non-small Cell Lung Cancer Patients.
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2019
Completion date
October 21, 2024
Enrollment
41 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer